Yes, that is something that makes the weight loss look better. Other comments are that phase 1 studies are prone to sampling error. Also, I'd like to know male vs female split (Female more likely to lose weight in study) .
I'm much more interested in tolerability/side effects. I think they are hiding something there. Why not release the data? If that was good, they would have released it. Instead they have been pretty coy. I just saw ,Novo Nordisk's Executive Vice President, Development, Martin Holst Lange made some comments:
Ok so now discontinuation rate was around 20% which isn't bad but its not great either. Guess he didn't want to say if AE's were mild or moderate or if they had any SAE's that led to discontinuation.
"People are best convinced by reasons they discover themselves"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.